B
텔콘RF제약
200230KOSDAQ59.5 / 100
Reference Date: 2026-10-23
Financial Score24.0 / 40
News Sentiment12.5 / 25
Momentum11.0 / 20
Disclosure12.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Slightly down 1.9% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Telcon RF Pharmaceuticals primarily manufactures connectors and cable assemblies for wireless communication equipment, expanding into optical solutions and 5G FTTA (Fiber-To-The-Antenna) technology to strengthen its global market position. In the pharmaceutical and biotech sector, the company produces various dosage forms using KGMP-certified facilities and invests in new drug development.
Number of Employees
133people
Average Salary
55.3M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
0.19Industry Average 1.207.0Point
Half of industry avg (excellent)
ROE
-11.91Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
1.46Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 2023~20255.0 / 10 points
Revenue Growth Rate
2.0 / 3
Avg ▲9.1% (2-year basis)
Operating Profit Growth Rate
3.0 / 3
Avg ▲505.6% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -8.4% (declining, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position6.0Point
52w upper range (74%)
Current 2,125Won52-week high 2,72052-week low 360
1-month return3.0Point
1m -1.85% (flat)
Volume trend2.0Point
Volume decreasing
Detailed Disclosure
3 totalPositive 1Neutral 2Negative 0
- Neutral주식등의대량보유상황보고서(약식)2026-10-12
- Positive단일판매ㆍ공급계약체결(자율공시)2026-10-02
- Neutral주요사항보고서(자기전환사채만기전취득결정)2026-09-29